Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urothelial carcinoma is the ninth most common malignant neoplasm worldwide. nearly in all human tumors, actin filaments are involved in lamellopodia or cellular extensions. Cortactin is involved in fixing the actin assembly to enhance cellular penetration. Assessment of Cortactin expression in invasive and non-invasive urothelial carcinoma and recording any significant different expressions may have benefits in developing more effective anticancer chemotherapeutic agents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcome of Treating Bladder Cancer in Sohag University Hospital

NCT05082818

Bladder Cancer

COMPLETED

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Tissues From Egyptian Male Patients and Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder Cancer.

NCT06289270

Microbiota in Patients With Urinary Bladder Carcinoma in Urine and Cancer Tissues

RECRUITING

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

NCT03591367

Bladder Cancer Bladder Disease Bladder Neoplasm +1 more

COMPLETED NA

The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor.

NCT04603612

Bladder Cancer

COMPLETED NA

SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

NCT05429710

Urinary Bladder Neoplasm

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bladder carcinoma is the 9th most prevalent cancer worldwide. Mostcases are diagnosed in men. Bladder carcinoma is categorized into three disticly different categories; non- muscle invasive, muscle invasive and metastatic bladder carcinoma. Vast majority of all bladder carcinomas are diagnosed as urothelial carcinoma (UC). Squamous cell carcinoma (SCC), adenocarcinoma and other rare types represent the remaining 10%. In Egypt, bladder carcinoma is ranked as the most prevalent cancer . The most important etiological causes for such disease in Egypt are festation by S. haematopium and Cigarette smoking. Cortactin is a 63-65 kDa protein, encoded by a gene located on 11q13. Cortactin activates and binds to Arp2/3 and stabilizes the branched Actin networks. Invadopodia are Actin-rich cellular protrusions, associated with enhanced proteolytic activities in the invasive regions of carcinomas. it is also incorporated in invadopodia, Cortactin expression is enhanced once or rapidly following secretions of transmembrane metalloproteinase, MT1-MMP. Extracellular matrix (ECM) proteolytic cleavage develops soon after secretion of MT1-MMP and Cortactin. increased secretion of Cortactin was studied in a lot of malignant tumors, including melanoma, mammary, pancreatic duct, hepatocellular and colorectal adenocarcinomas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urothelial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

formalin fixed and paraffin embedded blocks of urinary bladder malignant neoplasms will be obtained and sectioned. from each block, one tissue section will be stained by H\&E, other section will be stained immunohistochemically by anti Cortactin antibodies.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with invasive and non invasive urothelial carcinoma

patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.

Group Type OTHER